0000950170-24-088538.txt : 20240731
0000950170-24-088538.hdr.sgml : 20240731
20240731160509
ACCESSION NUMBER: 0000950170-24-088538
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240729
FILED AS OF DATE: 20240731
DATE AS OF CHANGE: 20240731
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ZANTE GREG
CENTRAL INDEX KEY: 0001264949
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37355
FILM NUMBER: 241161878
MAIL ADDRESS:
STREET 1: C/O SANGAMO BIOSCIENCES, INC STE-A-100
STREET 2: POINT RICHMOND TECH, 501 CANAL BLVD,
CITY: RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viking Therapeutics, Inc.
CENTRAL INDEX KEY: 0001607678
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461073877
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-704-4660
MAIL ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
ownership.xml
4
X0508
4
2024-07-29
0001607678
Viking Therapeutics, Inc.
VKTX
0001264949
ZANTE GREG
C/O VIKING THERAPEUTICS, INC.
9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO
CA
92121
false
true
false
false
Chief Financial Officer
false
Common Stock, par value $0.00001 per share
2024-07-29
4
A
false
6667
0
A
181521
D
Common Stock, par value $0.00001 per share
2024-07-29
4
A
false
21667
0
A
203188
D
Common Stock, par value $0.00001 per share
2024-07-30
4
S
false
12662
56.96
D
190526
D
Common Stock, par value $0.00001 per share
2024-07-30
4
S
false
2974
57.71
D
187552
D
Common Stock, par value $0.00001 per share
2024-07-30
4
S
false
500
58.71
D
187052
D
The reported securities were subject to a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal.
The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal.
These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.46 to $57.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.46 to $58.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.54 to $58.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ Michael Morneau as Attorney-in-Fact
2024-07-31